Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report published on Friday morning,Benzinga reports. They ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $284.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan ...
Science Daily9h
Research achieves gene-editing breakthrough that could improve treatment for liver disease, other disorders
Researchers developed a new gene-editing strategy that dramatically boosts the effectiveness of gene therapies in the liver, a breakthrough that could lead to new treatments for about 700 genetic ...